Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Evaluation of the effects on peripheral and central haemodynamics parameters, safety, and tolerance of three-hour intravenous perfusion (0.1 mg/kg) of ivabradine given to severe congestive heart failure patients.

Trial Profile

Evaluation of the effects on peripheral and central haemodynamics parameters, safety, and tolerance of three-hour intravenous perfusion (0.1 mg/kg) of ivabradine given to severe congestive heart failure patients.

Completed
Phase of Trial: Phase II

Latest Information Update: 03 Aug 2012

At a glance

  • Drugs Ivabradine (Primary)
  • Indications Heart failure
  • Focus Therapeutic Use
  • Most Recent Events

    • 15 Jun 2011 Actual end date (Feb 2006) added as reported by ClinicalTrials.gov.
    • 15 Jun 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 29 Oct 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top